A new clinical trial is giving hope to those recently diagnosed with Parkinson’s disease, showing that a GLP-1 receptor drug may slow the progression of symptoms that affect fine motor skills by having a protective response on the nervous system. The drug, lixisenatide, has been on the market for years and as it continues to be studied, there could be promise with other GLP-1 receptors like semaglutide, the ingredient in the popular drug Ozempic. The lixisenatide study included those with early-stage Parkinson’s disease and found that those given the type 2 diabetes drug showed no deterioration of motor skills after 12 months. Learn more about the GLP-1 drug helping Parkinson’s.
